Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Acetylcysteine

Preparation Calculator

USE IF: Paracetamol/acetaminophen overdose, selected mucolytic use, specialist toxicology indications

AVOID IF: No clear indication without toxicology context; monitor carefully if asthma/reactive airway disease

Acetylcysteine (NAC)

Glutathione precursor — antidote for paracetamol/acetaminophen toxicity; also mucolytic (route/indication-specific)

ToxicologyERParacetamolOverdoseIV infusionPoison centerMucolyticHigh-yield

Indication

Paracetamol overdose • Acetaminophen toxicity • Mucolytic use

At a glance

INDICATIONS (CORE USE)

- Paracetamol/acetaminophen overdose - Prevention/treatment of hepatic injury after toxic ingestion - Mucolytic use (selected)

ADULT DOSE (STANDARD)

Paracetamol overdose: protocol-based IV or oral regimen (weight-based, staged) Onset: most effective when started early; may still be indicated late in high-risk or toxic cases per guidance

MAX DOSE

Not a single universal max — use poison-center/institutional protocol (includes infusion duration, weight cap if applicable, extension rules)

Route

IV • PO • inhaled/nebulized depending on indication

PEDIATRIC DOSE

Weight-based and protocol-driven (poison center / institutional protocol)

Do not miss

Must-not-miss safety points

Major warning

- Start early in paracetamol overdose — do not delay while waiting if high-risk - Late presentation may still benefit → toxicology / poison center guidance - IV reactions can mimic allergy but are often anaphylactoid - Dosing is protocol-based and weight-dependent

Institutional protocol required

Dosing for this medication is not a substitute for your hospital order set, pharmacy verification, or specialty protocol. Use only with an approved institutional pathway, continuous monitoring, and independent double-check where policy requires.

FMBM beta: decision support only — not medical advice or a prescribing system.

Indications

INDICATION: Paracetamol overdose • Acetaminophen toxicity • Mucolytic use

Primary

  • Paracetamol/acetaminophen overdose

Secondary

  • Mucolytic therapy
  • Selected toxicology uses under specialist guidance

Institutional protocol required

Dosing for this medication is not a substitute for your hospital order set, pharmacy verification, or specialty protocol. Use only with an approved institutional pathway, continuous monitoring, and independent double-check where policy requires.

Numeric examples in this monograph are illustrative only when present — always follow your verified institutional protocol and product labeling.

FMBM beta: decision support only — not medical advice or a prescribing system.

Dosing

STANDARD (ADULT PO)

Overdose care: use institutional or poison-center protocol (IV and/or oral per pathway)

ADULT DOSE

STANDARD (ADULT — OVERDOSE): - Use institutional / poison-center protocol only - IV regimen is weight-based and staged (rates/durations are protocol-specific) - Oral regimen exists but is less commonly used in many acute-care pathways (region/protocol dependent)

PEDIATRIC DOSE

Weight-based and protocol-driven; pay attention to fluid load with IV protocols in small children / low body weight when applicable

MAX DOSE

Capped and staged per protocol (including extension/repeat-dose rules) — not freestyle

Practical Note

- Do not freestyle dosing - Use actual protocol for dose, infusion duration, weight cap (if applicable), and repeat/extend treatment if labs remain abnormal or toxicology says continue

Warnings

Clinical warnings

  • Use only with an approved institutional order set and pharmacy verification — this monograph is clinical decision support, not standalone prescribing authority.
  • Anaphylactoid infusion reaction (IV)
  • Nausea / vomiting
  • Bronchospasm risk in susceptible patients (reactive airways, inhaled use)
  • Fluid overload risk with IV protocols in small children / low body weight if not adjusted

Adverse effects

  • Rash
  • Flushing
  • Wheeze
  • Nausea
  • Vomiting

Contraindications

  • Known severe hypersensitivity to the acetylcysteine formulation (absolute manufacturer-specific)
  • Do not over-restrict: in true paracetamol toxicity, benefit of indicated NAC usually outweighs reaction risk (manage reaction + seek toxicology input)

Drug interactions

  • Few clinically significant drug–drug interactions in typical toxicology use
  • Activated charcoal may reduce oral NAC absorption if co-administered — separate timing / follow poison center guidance

Special populations

Pediatrics

Weight-based and protocol-driven (poison center / institutional protocol)

Pregnancy

Pregnancy: Treat paracetamol overdose promptly; do not delay indicated NAC.

Lactation

See product labeling; in overdose, prioritize time-critical toxicology care.

Renal impairment

In overdose care, follow protocol adjustments if relevant; not typically a reason to withhold clearly indicated NAC for paracetamol toxicity

Hepatic impairment

Hepatic injury: continue/extend NAC per toxicology and labs; injury is the problem being treated, not a blanket reason to stop without guidance

Elderly

Protocol-based dosing and infusion monitoring; comorbid reactive airway/asthma: heightened bronchospasm vigilance with IV and inhaled routes

Administration

IV: - Protocol-based staged infusion - Monitor for infusion reactions - If reaction: pause/slow and treat per protocol; restart when safe if still indicated (reaction does not always mean never restart) PO: - Poor taste / vomiting common — antiemetic support may be needed per pathway Inhaled: - Mucolytic use; bronchospasm possible in susceptible patients

Monitoring

  • Monitor: - Paracetamol level (per nomogram / protocol window) - ALT / AST - INR / PT - Creatinine - Signs/symptoms of infusion reaction (flush, wheeze, hypotension, angioedema pattern)
  • Recheck: - Per overdose protocol timing (labs and vitals) - Before stopping NAC in late presentation or with abnormal/moving labs; DO NOT stop blindly if paracetamol still detectable or transaminases are still rising without toxicology sign-off at 48–72h
  • Hold / reassess: - Severe infusion reaction (treat, then toxicology decision on restart) - Worsening liver injury: continue/escalate per specialist guidance, not ad hoc unilateral early cessation in evolving toxicity

Overdose / toxicity

Clinical Picture

NAC “toxicity” is most often anaphylactoid reaction or fluid effects Excess fluid load is possible with IV protocols (especially in small children) if not protocol-adjusted

Immediate Actions

Severe reaction: stop or slow infusion, supportive care, treat bronchospasm as indicated Reassess need to restart — NAC may still be life-saving in paracetamol poisoning

Antidote

None specific for NAC reaction

Decontamination

Not applicable in typical NAC care; in accidental massive IV dosing — supportive care, poison center

Escalation

Refractory anaphylactoid/angioedema, persistent hemodynamic collapse, or iatrogenic volume overload — escalate to ICU/ED senior + toxicology

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Most important use = paracetamol overdose
  • Early treatment is best, but late treatment can still matter

Clinical

  • “Reaction” does not automatically mean permanent discontinuation — use toxicology for extended course

Safety

  • Most dangerous error = stopping NAC while paracetamol remains detectable or liver injury is evolving

Pharmacy Tool

Preparation Calculator

Acetylcysteine 10% ophthalmic solution

ophthalmic solution · ophthalmic

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- Replenishes glutathione stores - Supports detoxification of toxic paracetamol metabolite (NAPQI pathway)

Mechanism of action

- Glutathione precursor → detoxifies NAPQI in paracetamol toxicity - Mucolytic effect via disulfide bond disruption in mucus

Common brand names

Saudi Arabia

Parvolex, Acetadote, Fluimucil

Global

N-acetylcysteine, Acetylcysteine, NAC, Mucomyst, (placeholder — verify local formulation)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Local poison center and institutional paracetamol/NAC protocol
  • Product labeling (IV, oral, inhaled acetylcysteine) where relevant
  • National toxicology / poison center resources for nomogram, duration, and extension of therapy